ZIVO Bioscience (NASDAQ:ZIVO) versus Immunocore (NASDAQ:IMCR) Head-To-Head Contrast

ZIVO Bioscience (NASDAQ:ZIVO) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Profitability

This table compares ZIVO Bioscience and Immunocore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	-11,068.75%	N/A	-1,308.44%
Immunocore	-19.16%	-14.68%	-6.68%

Earnings & Valuation

This table compares ZIVO Bioscience and Immunocore”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$30,000.00	2,373.20	-$7.78 million	($5.26)	-3.88
Immunocore	$280.91 million	5.91	-$55.29 million	($1.22)	-27.19

ZIVO Bioscience has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ZIVO Bioscience has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for ZIVO Bioscience and Immunocore, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0	1	0	0	2.00
Immunocore	0	2	11	0	2.85

Immunocore has a consensus price target of $79.82, suggesting a potential upside of 143.42%. Given Immunocore’s stronger consensus rating and higher probable upside, analysts plainly believe Immunocore is more favorable than ZIVO Bioscience.

Insider & Institutional Ownership

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 9.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Immunocore beats ZIVO Bioscience on 9 of the 14 factors compared between the two stocks.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.